TABLE 2.
Summary of studies examining seroprevalence of circulating immunoglobulin G against vaccine‐preventable infections.
| Author (year) | Angelidakis et al. (2022) 110 | Bansal et al. (2021) 111 | Rahman et al. (2019) 116 | Hill et al. (2019) 113 | Shah et al. (2021) 114 | Walti et al. (2021) 115 |
|---|---|---|---|---|---|---|
| Design | Prospective | Retrospective | Prospective | Retrospective | Retrospective | Retrospective |
| Population | 38 | 40 | 8 | 40 | 21 | 85 |
| Malignancy | Mixed | Lymphoma | DLBCL | Mixed | DLBCL | Mixed |
| CAR‐T target | CD19+ | CD19+ | CD19+ | CD19+ | CD19+ | CD19+ BCMA |
| Prior HCT | 5 (13) | 25 (63) | Not reported | Not reported | 5 (24) | 32 (49) |
| IVIg | 3/31 (10) | 23 (58) | Not reported | Excluded | 9 (43) | Excluded |
| Study baseline | Pre‐CAR‐T | Pre‐CAR‐T | Pre‐CAR‐T | Pre‐CAR‐T | 12 months from CAR‐T | Median 20 months from CAR‐T |
| VZV | – | 31/38 (82) | – | – | 18 (87) | 23/26 (90) |
| Hepatitis A | – | 16/34 (47) | – | – | – | 12/28 (41) |
| Hepatitis B | – | 8/35 (23) | – | – | 11 (52) | 11/28 (40) |
| Measles | – | 32/38 (84) | 6/8 (75) | 22/40 (55) | 16 (77) | 24/30 (80) |
| Mumps | – | 10/12 (83) | 5/8 (63) | – | 18 (86) | 15/30 (50) |
| Rubella | – | 33/38 (87) | 3/8 (38) | – | 17 (81) | 27/30 (90) |
| Pneumococcal | 8/37 (22) | – | – | – | 0 (0) | 0/25 |
| Tetanus | 37/37 (100) | 36/37 (97) | 8/8 (100) | – | 20 (95) | 25/28 (90) |
| Diphtheria | 35/37 (95) | – | 7/8 (88) | – | – | 25/28 (90) |
| Pertussis | – | – | 0/8 (0) | – | 11 (50) | 0/14 |
| Study endpoint | 6 months post‐CAR‐T | 3 months post‐CAR‐T | N/A | 12 months post‐CAR‐T | N/A | N/A |
| VZV | – | 26/27 (96) | – | – | – | – |
| Hepatitis A | – | 22/31 (71) | – | – | – | – |
| Hepatitis B | – | 22/31 (71) | – | – | – | – |
| Measles | – | 22/27 (81) | 6/8 (75) | 21/40 (53) | – | – |
| Mumps | – | 26/27 (96) | 3/8 (63) | – | – | – |
| Rubella | – | 26/27 (96 | 5/8 (38) | – | – | – |
| Pneumococcal | 2/3 (67) | 5/35 (14) | – | – | – | – |
| Tetanus | 13/13 (100) | 27/27 (100) | 8/8 (100) | – | – | – |
| Diphtheria | 11/13 (85) | – | 7/8 (88) | – | – | – |
| Pertussis | – | – | 0/8 (0) | – | – | – |
Abbreviations: BCMA, B‐cell maturation antigen; CAR‐T, chimeric antigen receptor T cell; CD19, cluster of differentiation 19; DLBCL, diffuse large B‐cell lymphoma; HCT, hematopoietic cell transplant; IVIg, intravenous immunoglobulin; VZV, varicella zoster virus.